ScreenerHero

BDTXBlack Diamond Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · blackdiamondtherapeutics.com
2.210USD+0.91%Mkt Cap: 126.97M $P/E: —

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is s…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap126.97M $
Enterprise Value29.99M $
Revenue (TTM)0 $
Gross Profit0 $
Net Income (TTM)22.37M $
Revenue/Share0.0000 USD
Last Price2.210 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.15
PEG—
EV/EBITDA-0.68
EV/Revenue—
P/SInfinity
P/B1.29
EPS (TTM)-0.74
EPS (Forward)-1.00
52W Range
1.60018% of range4.940
52W High4.940 USD
52W Low1.600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin31.95%
ROE19.93%
ROA15.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF29.61M $
CapEx (TTM)—
FCF Margin—
FCF Yield-18.57%
Net Debt-93.54M $
Net Debt/EBITDA2.11
Balance Sheet
Debt/Equity0.17
Current Ratio7.28
Quick Ratio6.97
Book Value/Sh1.673 USD
Cash/Share1.923 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.00 USD
Upside (mean)+352.5%
Target Range8.000 USD – 14.00 USD
$8.000+352.5% to mean$14.00
# Analysts7
Ownership
Shares Out.57.45M
Float52.60M
Insiders0.65%
Institutions72.52%
Short Interest
Short Ratio5.2d
Short % Float14.67%
Short % Out.10.20%
Shares Short5.86M
Short (prev mo.)4.50M
Technical
SMA 501.850 (+19.5%)
SMA 2002.506 (-11.8%)
Beta3.29
S&P 52W Chg18.16%
Avg Vol (30d)664.22K
Avg Vol (10d)637.19K
Technical Indicators
RSI (14)68.1
MACD0.0748
MACD Signal0.0326
MACD Hist.+0.0423
BB Upper2.248 USD
BB Middle1.899 USD
BB Lower1.551 USD
BB Width36.74%
ATR (14)0.1130 USD
Vol Ratio (20d)1.04x